Strong Earnings and Operating EPS Growth
Net income of $271 million ($3.39 per share) in Q1 2026 versus $255 million ($3.01 per share) a year ago; net operating income per share of $3.43, an increase of 12% year-over-year (from $3.07).
Improved Book Value and Return on Equity
GAAP return on equity through March 31 of 17.9%; book value per share $77.30. Excluding AOCI, return on equity 14% and book value per share $98.56, up 12% year-over-year.
Premium Revenue and Underwriting Performance
Total premium revenue grew 6% in Q1; company expects ~7% premium growth for full year. Life premium revenue up 3% to $853 million and life underwriting margin up 3% to $349 million (life margin 41% in Q1). Health premium revenue up 13% to $417 million and health underwriting margin up 12% to $95 million (health margin ~23% in Q1).
Exceptional Sales Momentum in Health and Solid Life Sales
Total life net sales grew 6% and total health net sales grew 58% in Q1. Notable divisional performance: United American General Agency net health sales $62 million (up ~ $34 million year-over-year) and Family Heritage net health sales up 22% to $33 million.
Distribution Wins and Agency-Level Growth
American Income life premiums +5% to $459M and underwriting margin +7% to $209M; Liberty National life net sales +13% and average producing agent count +9% year-over-year; Family Heritage average producing agent count +10% and health premiums +10%.
Investments and Yield Profile
Invested assets $22 billion (including $19.1B fixed maturities). Earned yield on long-term invested assets 5.5% in Q1; fixed-maturity purchases in Q1 averaged 6.23% yield. Company expects full-year long-term investment yield 5.45%–5.50% and plans ~$1.1B–$1.2B in investments at an average yield of 6.3%–6.5%.
Capital Return and Liquidity Actions
During Q1 the company repurchased ~1.4 million shares for ~$205 million and returned ~$225 million to shareholders including ~$20 million in dividends. Increased annual dividend rate by 22% and raised full-year share repurchase range to $560M–$610M.
Strong Capital and Solvency Metrics
Consolidated RBC for U.S. insurance subsidiaries was 316% at year-end 2025, providing approximately $95 million of excess capital above the company's 300% minimum target; target consolidated RBC range 300%–320%.
Raised and Refined 2026 Guidance
Net operating diluted EPS guidance of $15.40–$15.90 for 2026 (approx. 8% growth at midpoint). Normalized EPS growth excluding assumption updates ~11% at midpoint; projected 3-year CAGR of normalized EPS ~11.5%. Company forecasts a pre-tax remeasurement benefit of $70M–$110M expected in Q3 (implying a one-quarter life margin of ~49%–54%).
Incremental Investment Income and Excess Investment Income Growth
Net investment income of $290 million (up 3% year-over-year) and excess investment income of $37 million (up ~$1 million year-over-year). Expected net investment income and required interest growth around 4% for full year, implying excess investment income growth of ~4%–4.5%.